Mental Health, Major depressive disorder
VNDAVanda Pharmaceuticals Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Bysanti™ (milsaperidone) in Mental Health, Major depressive disorder. The expected timing is based on the latest available company guidance and may change.
Q4 2024- Trial initiated. 2/13/25- Report results in 2026. 10/29/25:- Phase 3 Bysanti study as once-daily adjunctive treatment for MDD is enrolling patients, with results still expected in 2026. 02/11/26:- Phase 3 Bysanti adjunctive MDD trial continues enrolling; results remain expected in 2026. 08/05/26:- Ph3 adjunctive MDD results now expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.